Author(s):
Anushka Deore, Smita Kothmire, Akshay Khade, Suvarna Bhalerao
Email(s):
anushkadeore07@gmail.com
DOI:
10.52711/0975-4385.2025.00036 
Address:
Anushka Deore1*, Smita Kothmire2, Akshay Khade3, Suvarna Bhalerao3
1Department of Pharmacognosy, MET’S Institute of Pharmacy, Adgaon, Nashik, Maharashtra, 422003, India.
2Department of Pharmaceutics, MET’S Institute of Pharmacy, Adgaon, Nashik, Maharashtra, 422003, India.
3Department of Pharmacology, MET’S Institute of Pharmacy, Adgaon, Nashik, Maharashtra, 422003, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 3,
Year - 2025
ABSTRACT:
The purpose of this review article is to comprehensively evaluate the efficacy of standardised Ginkgo biloba extract (EGb 761) in enhancing cognition in Alzheimer's disease (AD) individuals. Ginkgo biloba, derived from the leaves of the Ginkgo tree, has a long-standing history of use for its neuroprotective and cognitive-enhancing properties. As the global prevalence of AD continues to rise and effective treatments remain limited, there is increasing interest in alternative and adjunctive therapies such as Ginkgo biloba. Research from preclinical studies and clinical trials suggests that Ginkgo biloba may exert its neuroprotective effects through multiple mechanisms, including antioxidant activity, reduction of neuroinflammation, and improved cerebral blood flow. Randomized controlled trials (RCTs) and observational studies indicate modest benefits in cognitive performance and a potential slowdown in disease progression, particularly in patients with mild-to-moderate AD. However, the results are inconsistent, largely due to variations in study design, dosages, and formulations. Meta-analyses highlight the necessity for standardized protocols to determine consistent efficacy. Ginkgo biloba shows promise as an adjunctive therapy for cognitive impairment in AD, offering a favourable safety profile and good tolerability. Nonetheless, there is a need for larger, multicentre, long-term studies to establish optimal dosages, treatment durations, and which patient subgroups are most likely to benefit. Gaining insight into its molecular mechanisms and exploring personalized treatment approaches could effectively bridge the gap between traditional herbal medicine and modern neurotherapeutics.
Cite this article:
Anushka Deore, Smita Kothmire, Akshay Khade, Suvarna Bhalerao. Efficacy of Standardized Ginkgo biloba Extract in Cognitive Enhancement for Alzheimer’s patients. Research Journal of Pharmacognosy and Phytochemistry. 2025; 17(3):219-8. doi: 10.52711/0975-4385.2025.00036
Cite(Electronic):
Anushka Deore, Smita Kothmire, Akshay Khade, Suvarna Bhalerao. Efficacy of Standardized Ginkgo biloba Extract in Cognitive Enhancement for Alzheimer’s patients. Research Journal of Pharmacognosy and Phytochemistry. 2025; 17(3):219-8. doi: 10.52711/0975-4385.2025.00036 Available on: https://rjpponline.org/AbstractView.aspx?PID=2025-17-3-6
REFERENCES:
1. Li X, Feng X, Sun X, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2019. Front Aging Neurosci. 2022; 14: 937486; doi: 10.3389/ fnagi.2022.937486.
2. Prince M, Guerchet M, Prina M. The global impact of dementia. 2013-2050. 2013.
3. H Y D, Rajashekhar U. Alzheimer’s Disease: An Outline of Therapeutic Interventions by different Approaches. RJPPD. 2024; 226–232; doi: 10.52711/2321-5836.2024.00038.
4. Sanmugam K. Depression is a Risk Factor for Alzheimer Disease-Review. Rese Jour of Pharm and Technol. 2015; 8(8): 1056; doi: 10.5958/0974-360X.2015.00181.X.
5. Hardy J, Selkoe DJ. The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics. Science. 2002; 297(5580): 353–356; doi: 10.1126/science.1072994.
6. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020; 396(10248): 413–446; doi: 10.1016/S0140-6736(20)30367-6.
7. Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord. 2013; 6(1): 19–33; doi: 10.1177/1756285612461679.
8. Pache M, Kedar H, Kond S, et al. Pharmacological Management of Neurodegenerative Disorders: Current and Future Approaches. Int J Sci R Tech. 2025; 2(3): 405–520; doi: 10.5281/ZENODO.15074000.
9. Paillard T. Preventive effects of regular physical exercise against cognitive decline and the risk of dementia with age advancement. Sports Med – Open. 2015; 1(1): 20; doi: 10.1186/s40798-015-0016-x.
10. S. Stavrinou P, Andreou E, Aphamis G, et al. The Effects of a 6-Month High Dose Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins Supplementation on Cognitive Function and Functional Capacity in Older Adults with Mild Cognitive Impairment. Nutrients. 2020; 12(2): 325; doi: 10.3390/ nu12020325.
11. Poswal A, Kaur H. Effectiveness of Cognitive Enhancement Therapy on Vocational abilities and Cognitive Functioning of Inmates residing at destitute home of Punjab: A Quasi Experimental study. IJANM. 2023; 250–254; doi: 10.52711/2454-2652.2023.00056.
12. Mahadevan S, Park Y. Multifaceted Therapeutic Benefits of Ginkgo biloba L.: Chemistry, Efficacy, Safety, and Uses. Journal of Food Science. 2008; 73(1); doi: 10.1111/j.1750-3841.2007.00597.x.
13. Sahu D, Bhushan S, Das D, et al. Potential Ayurvedic Herbs for Neurodegenerative Diseases: A review. RJPPD. 2021; 69–74; doi: 10.52711/2321-5836.2021.00015.
14. DeKosky ST. Ginkgo biloba for Prevention of DementiaA Randomized Controlled Trial. JAMA. 2008; 300(19): 2253; doi: 10.1001/ jama.2008.683.
15. Gomathi S, Sundaram RS, Vijayabaskaran M, et al. Pedalium murex Linn leaves against LPS-induced oxidative stress, anxiety and depression behavioural alterations in rats. Rese Jour of Pharm and Technol. 2017; 10(5): 1333; doi: 10.5958/0974-360X.2017.00236.0.
16. Weinmann S, Roll S, Schwarzbach C, et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010; 10(1): 14; doi: 10.1186/1471-2318-10-14.
17. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Brit J Clinical Pharma. 1992; 34(4): 352–358; doi: 10.1111/j.1365-2125.1992.tb05642.x.
18. Packer L. Antioxidant Action of Ginkgo biloba Extract (EGB 761). In: Food and Free Radicals. (Hiramatsu M, Yoshikawa T, Inoue M. eds) Springer US: Boston, MA; 1997; pp. 75–84; doi: 10.1007/978-1-4899-1837-6_7.
19. DeFeudis FV. Effects of Ginkgo biloba extract (EGb 761) on gene expression: Possible relevance to neurological disorders and age‐associated cognitive impairment. Drug Development Research. 2002; 57(4): 214–235; doi: 10.1002/ddr.10151.
20. Vakhariya RR, Talokar SS, Salunkhe VR, et al. Cognitive Disorders and its Herbal Remedies. Rese Jour of Pharmac and Phytoch. 2017; 9(1): 42; doi: 10.5958/0975-4385.2017.00007.3.
21. Pangavhane R, Pache M. Phytochemicals in The Management of Diabetes Mellitus: A Comprehensive Review. Int J Sci R Tech. 2025; 2(4): 6–14; doi: 10.5281/zenodo.15122232.
22. Calderaro A, Patanè GT, Tellone E, et al. The Neuroprotective Potentiality of Flavonoids on Alzheimer’s Disease. IJMS. 2022; 23(23): 14835; doi: 10.3390/ijms232314835.
23. Wang K, Chen X. Protective effect of flavonoids on oxidative stress injury in Alzheimer’s disease. Natural Product Research. 2024; 1–28; doi: 10.1080/14786419.2024.2345760.
24. Awasthi M, Upadhyay AK, Singh S, et al. Terpenoids as promising therapeutic molecules against Alzheimer’s disease: amyloid beta- and acetylcholinesterase-directed pharmacokinetic and molecular docking analyses. Molecular Simulation 2018; 44(1): 1–11; doi: 10.1080/08927022.2017.1334880.
25. Lang D, Kiewert C, Mdzinarishvili A, et al. Neuroprotective effects of bilobalide are accompanied by a reduction of ischemia-induced glutamate release in vivo. Brain Research. 2011; 1425: 155–163; doi: 10.1016/j.brainres.2011.10.005.
26. Pache MM, Thorat AS, Mule RR, et al. Recent advances in the use of alkaloids as therapeutic agents: a pharmacognostic perspective. World Journal of Pharmaceutical Research. 2025; 14(2): 538–552.
27. Stein C, Hopfeld J, Lau H, et al. Effects of Ginkgo biloba Extract EGb 761, Donepezil and their Combination on Central Cholinergic Function in Aged Rats. J Pharm Pharm Sci. 2015; 18(4): 634; doi: 10.18433/J3WC8V.
28. Pai V, Shreedhara CS, Chandrashekar KS, et al. Cognitive Enhancement and Neuroprotective Effects of Ancient Ayurvedic Medicinal Plant Celastrus Paniculatus: An Overview. Rese Jour of Pharm and Technol. 2016; 9(8): 1295; doi: 10.5958/0974-360X.2016.00246.8.
29. Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Ayatollahi SA, Department of Pharmacognosy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran, et al. Ginkgo biloba modulates hippocampal BDNF expression in a rat model of chronic restraint stress-induced depression. Physiol Pharmacol. 2020; 24(4): 285–297; doi: 10.32598/ppj.24.4.20.
30. Gargouri B, Carstensen J, Bhatia HS, et al. Anti-neuroinflammatory effects of Ginkgo biloba extract EGb761 in LPS-activated primary microglial cells. Phytomedicine. 2018; 44: 45–55; doi: 10.1016/j.phymed.2018.04.009.
31. Sun L, Apweiler M, Tirkey A, et al. Anti-Neuroinflammatory Effects of Ginkgo biloba Extract EGb 761 in LPS-Activated BV2 Microglial Cells. IJMS. 2024; 25(15): 8108; doi: 10.3390/ijms25158108.
32. Yan F-L, Zheng Y, Zhao F-D. Effects of Ginkgo biloba extract EGb761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia. Acta Neuropathol. 2008; 116(5): 529–535; doi: 10.1007/s00401-008-0435-6.
33. Wolters FJ, Zonneveld HI, Hofman A, et al. Cerebral Perfusion and the Risk of Dementia: A Population-Based Study. Circulation. 2017; 136(8): 719–728; doi: 10.1161/ CIRCULATIONAHA.117.027448.
34. Raju S, Sivanesan SK, Gudemalla K, et al. Effect of Ginkgo biloba extract on Hematological and Biochemical Alterations in Fluoride Toxicity in Wistar rats. Rese Jour of Pharm and Technol. 2019; 12(8): 3915; doi: 10.5958/0974-360X.2019.00674.7.
35. Liu X, Hao W, Qin Y, et al. Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer’s disease. Brain, Behavior, and Immunity. 2015; 46: 121–131; doi: 10.1016/j.bbi.2015.01.011.
36. Kuruvella S, Reddy Yellu N. Naringi crenulata leaf extract alleviates Beta Amyloid Protein Induced Alzheimers disease in mice. RJPT. 2024; 2732–2738; doi: 10.52711/0974-360X.2024.00428.
37. Tu J-L, Chen W-P, Cheng Z-J, et al. EGb761 ameliorates cell necroptosis by attenuating RIP1-mediated mitochondrial dysfunction and ROS production in both in vivo and in vitro models of Alzheimer’s disease. Brain Research. 2020; 1736: 146730; doi: 10.1016/j.brainres.2020.146730.
38. Tchantchou F, Xu Y, Wu Y, et al. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease. FASEB j. 2007; 21(10): 2400–2408; doi: 10.1096/fj.06-7649com.
39. Islam M, Ramanjaneyulu J, Babu DV, et al. Studies on Memory Enhancing Property of Bravobol-A Polyherbal Formulation in Experimentally Induced Alzheimers Disease in Experimental Animals. Asia Journ of Resear in Pharmac Sci. 2015; 5(2): 103; doi: 10.5958/2231-5659.2015.00017.X.
40. Zhao J, Cheng SW, Ng W-L, et al. Identification of the in vivo relevant dissolution media for the three active components in EGb 761 tablet for better correlation with their pharmacokinetics in healthy subjects. European Journal of Pharmaceutical Sciences. 2020; 154: 105515; doi: 10.1016/j.ejps.2020.105515.
41. Cui M, You T, Zhao Y, et al. Ginkgo biloba extract EGb 761® improves cognition and overall condition after ischemic stroke: Results from a pilot randomized trial. Front Pharmacol 2023; 14: 1147860; doi: 10.3389/fphar.2023.1147860.
42. Ihl R, Tribanek M, Bachinskaya N, et al. Efficacy and Tolerability of a Once Daily Formulation of Ginkgo biloba Extract EGb 761® in Alzheimer’s Disease and Vascular Dementia: Results from a Randomised Controlled Trial. Pharmacopsychiatry. 2012; 45(02): 41–46; doi: 10.1055/s-0031-1291217.
43. Herrschaft H, Nacu A, Likhachev S, et al. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. Journal of Psychiatric Research. 2012; 46(6): 716–723; doi: 10.1016/j.jpsychires.2012.03.003.
44. Dodge HH, Zitzelberger T, Oken BS, et al. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology. 2008; 70(19_part_2): 1809–1817; doi: 10.1212/01.wnl.0000303814.13509.db.
45. Liu H, Ye M, Guo H. An Updated Review of Randomized Clinical Trials Testing the Improvement of Cognitive Function of Ginkgo biloba Extract in Healthy People and Alzheimer’s Patients. Front Pharmacol. 2020; 10: 1688; doi: 10.3389/fphar.2019.01688.
46. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Dementia and Cognitive Improvement Group. ed. Cochrane Database of Systematic Reviews. 2009; doi: 10.1002/14651858.CD003120.pub3.
47. Millard LAC, Fernández-Sanlés A, Carter AR, et al. Exploring the impact of selection bias in observational studies of COVID-19: a simulation study. International Journal of Epidemiology. 2023; 52(1): 44–57; doi: 10.1093/ije/dyac221.
48. Patten SB. Selection bias in studies of major depression using clinical subjects. Journal of Clinical Epidemiology. 2000; 53(4): 351–357; doi: 10.1016/S0895-4356(99)00215-2.
49. Beck CA. Selection bias in observational studies: Out of control? Neurology. 2009; 72(2): 108–109; doi: 10.1212/ 01.wnl.0000339046.10288.fb.
50. Geneletti S, Richardson S, Best N. Adjusting for selection bias in retrospective, case-control studies. Biostatistics. 2008; 10(1): 17–31; doi: 10.1093/biostatistics/kxn010.
51. Shapland CY, Gkatzionis A, Hemani G, et al. Use of Genetic Correlations to Examine Selection Bias. 2023; doi: 10.1101/ 2023.04.04.23288120.
52. Wu Y, Ma X, Zhou Q, et al. Selection of crown type provides a potential to improve the content of isorhamnetin in Ginkgo biloba. Industrial Crops and Products. 2020; 143: 111943; doi: 10.1016/j.indcrop.2019.111943.
53. Hort J, Duning T, Hoerr R. Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review. Dove Medical Press. 2023; 19: 647–660; doi: 10.2147/ndt.s401231.
54. Yang G, Wang Y, Sun J, et al. Ginkgo biloba for Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Bentham Science Publishers. 2015; 16(5): 520–528; doi: 10.2174/ 1568026615666150813143520.
55. Schulz V. Ginkgo extract or cholinesterase inhibitors in patients with dementia: What clinical trials and guidelines fail to consider. Phytomedicine. 2003; 10: 74–79; doi: 10.1078/1433-187X-00302.
56. Filho CEC, Loss LB, Marcolongo-Pereira C, et al. Advances in Alzheimer’s Disease’s Pharmacological Treatment. Frontiers Media. 2023; 14; doi: 10.3389/fphar.2023.1101452.
57. Mehta MG, Adem A, Sabbagh MN. New Acetylcholinesterase Inhibitors for Alzheimer’s Disease. Hindawi Publishing Corporation. 2011; 2012: 1–8; doi: 10.1155/2012/728983.
58. Hashiguchi M, Ohta Y, Shimizu M, et al. Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia. BioMed Central. 2015; 1(1): doi: 10.1186/s40780-015-0014-7.
59. Zhang H, Huang L, Zhong Y-B, et al. An Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and Dementia. Frontiers Media. 2016; 8; doi: 10.3389/ fnagi.2016.00276.
60. Mahady GB. Ginkgo biloba: A Review of Quality, Safety, and Efficacy. Wiley. 2001; 4(3): 140–147; doi: 10.1046/j.1523-5408.2001.00135.x.
61. Chan P-C, Xia Q, Fu PP. Ginkgo biloba Leave Extract: Biological, Medicinal, and Toxicological Effects. 2023.
62. Diamond BJ, Shiflett SC, Feiwel N, et al. Ginkgo biloba Extract: Mechanisms and Clinical Indications. Elsevier BV 2000; 81(5): 668–678; doi: 10.1016/s0003-9993(00)90052-2.
63. Stoddard GJ, Archer M, Shane‐McWhorter L, et al. Ginkgo and Warfarin Interaction in a Large Veterans Administration Population. National Institutes of Health. 2015; 2015: 1174–83.
64. Bent S, Goldberg H, Padula A, et al. Spontaneous bleeding associated with Ginkgo biloba. Springer Science+Business Media. 2005; 20(7): 657–661; doi: 10.1007/s11606-005-0114-4.
65. Therapeutics J of P, undefined CP. Safety and efficacy of ginkgo (Ginkgo biloba) during pregnancy and lactation. 2018.
66. Bone K. Potential Interaction of Ginkgo biloba Leaf with Antiplatelet or Anticoagulant Drugs: What Is the Evidence? Wiley. 2008; 52(7): 764–771; doi: 10.1002/mnfr.200700098.
67. Birks J, Evans JG. Ginkgo biloba for Cognitive Impairment and Dementia. Elsevier BV. 2009; doi: 10.1002/ 14651858.cd003120.pub3.
68. Abel ZDV, Roope LSJ, Duch R, et al. Access to healthcare services during the COVID-19 pandemic: a cross-sectional analysis of income and user-access across 16 economically diverse countries. BioMed Central. 2024; 24(1): doi: 10.1186/s12889-024-20147-y.
69. Burke SL, Hu T, Naseh M, et al. Factors influencing attrition in 35 Alzheimer’s Disease Centers across the USA: a longitudinal examination of the National Alzheimer’s Coordinating Center’s Uniform Data Set. Springer Science+Business Media. 2018; 31(9): 1283–1297; doi: 10.1007/s40520-018-1087-6.
70. Clostre F. [Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000]. National Institutes of Health. 1999; 57 Suppl 1: 1S8-88.
71. Sun M, Chai L, Lü F, et al. Efficacy and Safety of Ginkgo biloba Pills for Coronary Heart Disease with Impaired Glucose Regulation: Study Protocol for a Series of N‐of‐1 Randomized, Double‐Blind, Placebo‐Controlled Trials. Hindawi Publishing Corporation. 2018; 2018(1): doi: 10.1155/2018/7571629.
72. Pache MM, Pangavhane RR, Dhotre SR, et al. Cognitive Behavioural Therapy: The Treatment of Insomnia and Depression. Int J Pharm Sci Rev Res 2024; 84(11); doi: 10.47583/ ijpsrr.2024.v84i11.005.
73. Li D, Ma J, Wei B, et al. Effectiveness and Safety of Ginkgo biloba Preparations in the Treatment of Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Frontiers Media. 2023; 15: doi: 10.3389/fnagi.2023.1124710.
74. Gauthier S, Schlaefke S. Efficacy and Tolerability of Ginkgo biloba Extract EGb 761® in Dementia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. 2023.
75. Anonymous. Review of Ginkgo biloba-Induced Toxicity, from Experimental Studies to Human Case Reports. 2023.
76. Giacobini E. Cholinesterase Inhibitor Therapy Stabilizes Symptoms of Alzheimer Disease. Lippincott Williams and Wilkins. 2000; 14(Supplement): S3–S10; doi: 10.1097/00002093-200000001-00002.
77. Koenig AM, Mechanic-Hamilton D, Xie SX, et al. Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-Controlled Crossover Study. 2023.
78. Brondino N, Silvestri AD, Re S, et al. A Systematic Review and Meta-Analysis ofGinkgo bilobain Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine. Hindawi Publishing Corporation. 2013; 2013: 1–11; doi: 10.1155/ 2013/915691.
79. Zheng Y, Xie Y, Qi M, et al. Ginkgo biloba Extract Is Comparable With Donepezil in Improving Functional Recovery in Alzheimer’s Disease: Results From a Multilevel Characterized Study Based on Clinical Features and Resting-State Functional Magnetic Resonance Imaging. Frontiers Media. 2021;12; doi: 10.3389/fphar.2021.721216.
80. Ding J, Davis‐Plourde K, Sedaghat S, et al. Antihypertensive Medications and Risk for Incident Dementia and Alzheimer’s Disease: A Meta-Analysis of Individual Participant Data from Prospective Cohort Studies. Elsevier BV. 2019; 19(1): 61–70; doi: 10.1016/s1474-4422(19)30393-x.
81. Zuo W, Yan F, Zhang B, et al. Advances in the Studies of Ginkgo biloba Leaves Extract on Aging-Related Diseases. Buck Institute for Research on Aging. 2017; 8(6): 812–812; doi: 10.14336/ ad.2017.0615.
82. Pache MM, Pangavhane RR, Jagtap MN, et al. The AI-Driven Future of Drug Discovery: Innovations, Applications, and Challenges. Asian J Res Pharm Sci. 2025; 15(1): 61–67; doi: 10.52711/2231-5659.2025.00009.
83. Chiauzzi E, Rodarte C, DasMahapatra P. Patient-centered activity monitoring in the self-management of chronic health conditions. BioMed Central. 2015; 13(1); doi: 10.1186/s12916-015-0319-2.